MALVERN, Pa., February 10, 2021 (GLOBE NEWSWIRE) – Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focusing on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID. -19, announced today that it has closed the previously announced registered direct offer to sell a total of 3,000,000 shares of its ordinary share for a gross return of approximately $ 23 million before the placement agent’s fees and other expenses which is payable by Ocugen has been deducted.
HC Wainwright & Co. acted as the exclusive agent for the presentation.
Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditure, working capital and general and administrative expenses.
The shares of the ordinary shares described above were offered on the basis of a ‘shelf’ registration declaration (file no. 333-237456) submitted to the Securities and Exchange Commission (‘SEC’) on 27 March 2020 and on 5 May 2020 was declared effective. Such ordinary shares were offered only through a prospectus, including a prospectus supplement, which forms part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of ordinary shares have been filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus regarding the offering of shares in ordinary shares can be obtained on the SEC’s website at http://www.sec.gov or by contacting HC Wainwright & Co., LLC at 430 to connect. Park Avenue, 3rd Floor, New York, NY 10022, by email: [email protected] or by phone: (646) 975-6996.
This press release does not constitute an offer to sell or a request for an offer to purchase these securities, nor will any sale of these securities take place in any state or other jurisdiction in which such offer, invitation or sale would be unlawful. be before the registration or qualification under the security laws of such state or other jurisdiction.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focusing on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”, and our new candidate for biological products aims to better treat patients with minor diseases such as wet age-related macular degeneration, diabetes to offer. macular edema, and diabetic retinopathy. Visit www.ocugen.com for more information.
Warning about forward-looking statements
This press release contains forward – looking statements within the meaning of the Private Security Procedure Reform Act of 1995, which is subject to risks and uncertainties. Such forward-looking statements in this press release include, without limitation, the intended use of net proceeds from the registered direct offer. In some cases we may use terms such as ‘predict’, ‘believe’, ‘potential’, ‘proposed’, ‘continue’, ‘estimate’, ‘expect’, ‘expect’, ‘plan’, ‘intend’ “Power,” “can,” “power,” “will,” “must” or other words that convey uncertainty about future events or outcomes to identify these forward-looking statements, such statements are subject to numerous important factors, risks and uncertainties that may result in actual events or results differing materially from our current expectations, such as the market and other conditions.These and other risks and uncertainties are described in more detail in our periodic filing with the SEC, including the risk factors described in the section entitled “Risk Factors” in the Quarterly and Annual Reports We Submit to the SEC Any forward-looking statements we make in this press release apply only to the date of this press release. Except as required by law, we accept no obligation to update forward-looking statements in this press release, whether due to new information, future events or otherwise, after the date of this press release.
Corporate contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer and Head of Corporate Development
[email protected]
Media contact:
LaVoieHealth Sciences
Emmie Twombly
[email protected]
+1 857-389-6042